Aprea Therapeutics Receives FDA Fast Track Designation for Eprenetapopt in the Treatment of TP53 Mutant Acute Myeloid Leukemia (AML)

Matthew Durham
Omnidynamic Marketing

Amy Giles
Increasing Engagement

Matt Turner
Patient Affordability

David Linetsky
Point-of-Care Marketing

Suma Ramadas, PhD
Medical Affairs

Joey Cohen
Medication Adherence

Frank Burrell
Scientific Storytelling

Pat Purcell
Meeting Engagement

Brenda Snow
Authentic Patient Voice

Paul Theisen
Patient Acquisition

Liz Kane
Impactful Strategy

Daniel Sontupe
Market Access

Stacey Gandler
Brand Nourishment

Bud Bilanich
Success Coach